19 December 2025 - The US FDA today awarded national priority vouchers under the Commissioner’s National Priority Voucher pilot program to two investigational products for their potential to increase access through affordability for American patients.

The products are:

• Enlicitide decanoate — an oral PCSK9 inhibitor for lowering LDL cholesterol
• Sacituzumab tirumotecan — a trophoblast cell-surface antigen 2 (TROP2)-directed antibody drug conjugate

Read FDA press release